2023
Alcohol-mediated renal denervation in patients with hypertension in the absence of antihypertensive medications.
Pathak A, Rudolph U, Saxena M, Zeller T, Müller-Ehmsen J, Lipsic E, Schmieder R, Sievert H, Halbach M, Sharif F, Parise H, Fischell T, Weber M, Kandzari D, Mahfoud F. Alcohol-mediated renal denervation in patients with hypertension in the absence of antihypertensive medications. EuroIntervention 2023, 19: 602-611. PMID: 37427416, PMCID: PMC10493775, DOI: 10.4244/eij-d-23-00088.Peer-Reviewed Original ResearchConceptsSystolic blood pressureRenal denervationBlood pressureAntihypertensive medicationsRDN groupMedication burdenMean office blood pressureOffice systolic blood pressureSystolic BP 140Office blood pressurePrimary efficacy endpointMajor adverse eventsSystolic BP changeDiastolic blood pressureLower blood pressureRadiofrequency renal denervationLower medication burdenSignificant BP differencesMedication escalationEfficacy endpointSafety endpointAdverse eventsSham groupBP changesMedication washoutChocolate Touch Versus Lutonix Drug-Coated Balloon for Femoropopliteal Lesions in Diabetes: The Chocolate Touch Study.
Böhme T, Zeller T, Shishehbor M, Werner M, Brodmann M, Parise H, Holden A, Lichtenberg M, Parikh S, Kashyap V, Pietras C, Tirziu D, Beschorner U, Krishnan P, Niazi K, Wali A, Lansky A. Chocolate Touch Versus Lutonix Drug-Coated Balloon for Femoropopliteal Lesions in Diabetes: The Chocolate Touch Study. Journal Of Endovascular Therapy 2023, 15266028231179589. PMID: 37314243, DOI: 10.1177/15266028231179589.Peer-Reviewed Original ResearchLutonix drug-coated balloonDrug-coated balloonsPrimary safety endpointDM statusFemoropopliteal diseaseDiabetes mellitusSafety endpointFemoropopliteal lesionsSimilar safetyHigh-risk patient populationFemoropopliteal artery lesionsIschemic rest painNon-DM patientsSymptomatic femoropopliteal lesionsPrimary efficacy endpointMajor adverse eventsTherapy of choiceDrug-Coated BalloonMajor amputationRest painEfficacy endpointPrimary patencyAdverse eventsArtery lesionsDiabetes status
2022
Randomized Trial of Chocolate Touch Compared With Lutonix Drug-Coated Balloon in Femoropopliteal Lesions (Chocolate Touch Study)
Shishehbor MH, Zeller T, Werner M, Brodmann M, Parise H, Holden A, Lichtenberg M, Parikh SA, Kashyap VS, Pietras C, Tirziu D, Ardakani S, Beschorner U, Krishnan P, Niazi KA, Wali AU, Lansky AJ. Randomized Trial of Chocolate Touch Compared With Lutonix Drug-Coated Balloon in Femoropopliteal Lesions (Chocolate Touch Study). Circulation 2022, 145: 1645-1654. PMID: 35377157, DOI: 10.1161/circulationaha.122.059646.Peer-Reviewed Original ResearchConceptsLutonix drug-coated balloonDrug-coated balloonsEnd pointPrimary efficacy end pointPrimary safety end pointIndependent clinical events committeeIschemic rest painPrimary efficacy rateEfficacy end pointPrimary end pointSafety end pointClinical events committeeMajor adverse eventsRate of restenosisDrug-Coated BalloonNoninferiority end pointSafety event rateAverage lesion lengthMajor amputationPopliteal diseaseRest painBailout stentingEfficacy ratePrimary patencyAdverse events
2012
Characteristics and Outcomes of Patients With ST-Segment Elevation Myocardial Infarction Excluded from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial
Fiocca L, Guagliumi G, Rossini R, Parise H, Musumeci G, Sirbu V, Lortkipanidze N, Yu J, Mihalcsik L, Vassileva A, Valsecchi O, Gavazzi A, Mehran R, Stone G. Characteristics and Outcomes of Patients With ST-Segment Elevation Myocardial Infarction Excluded from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial. The American Journal Of Cardiology 2012, 111: 196-201. PMID: 23111141, DOI: 10.1016/j.amjcard.2012.09.019.Peer-Reviewed Original ResearchConceptsST-segment elevation myocardial infarctionAcute Myocardial Infarction trialKillip class IIIMyocardial Infarction trialOutcomes of patientsElevation myocardial infarctionHarmonizing OutcomesMyocardial infarctionMyocardial Infarction flow grade 3Major adverse cardiovascular eventsNet adverse clinical eventsClass IIIHORIZONS-AMI trialTrial eligible groupAdverse cardiovascular eventsHigh-risk featuresAdverse clinical eventsVentricular ejection fractionBroad inclusion criteriaFinal ThrombolysisMajor bleedingCardiovascular eventsCause mortalityAdverse eventsBaseline characteristics